X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Tryst with Pharma Stocks, Transparency in Ratings and More... - Views on News from Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  
The Equitymaster Research Digest

Tryst with Pharma Stocks, Transparency in Ratings and More...
Dec 8, 2015

A couple of months back, I gave you a heads up on the key signals of the Megatrend that we have been tracking in the pharma sector. But the sector is a complex one. Its ever-changing dynamics make it important to look at each and every businesses independently.

Now it seems our tryst with interesting healthcare and pharma stocks is here to stay. For two businesses, each with compelling business propositions, are soon to debut on the bourses.

We recently put up our view on the initial public offering of Dr Lal Path Labs. Apart from being unique among the listed healthcare companies, its business model offers scope for very high growth. However, it is competing with several other diagnostic chains, which all put together have just a 15% share of the Indian diagnostics industry.

The other company set to hit the primary market is India's fifth largest pharmaceutical company! Alkem Laboratories' large sales force sells more than 700 brands. The company has field force of more than 5,700 medical representatives. Among the various therapies the company offers, anti-infectives account for the biggest chunk.

To Read the Full Story, Subscribe or Sign In


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MARKET STATS